Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese Patent Office has decided to grant a patent for NexMed’s patent application entitled, 'Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction.' NexMed is a specialty CRO with a pipeline of product candidates based on the NexACT technology.
Subscribe to our email newsletter
The patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros and the underlying NexACT technology.
Bassam Damaj, president and CEO of NexMed, said: “We are very pleased with our first patent allowance for Vitaros in Japan. Throughout its history, the company has aggressively pursued intellectual property coverage for its technology and products under development.
“In addition to the newly allowed claims in Japan, we have corresponding coverage and protection for Vitaros in the major international markets.”
NexMed said that it is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.